A new class of pluripotent stem cell cytotoxic small molecules

Area of Science:

• Regenerative Medicine
• Stem Cell Biology
• Drug Discovery

Background:

• Pluripotent Stem Cell (PSC)-derived cell replacement therapies face teratoma formation risks from residual undifferentiated cells.
• Efficiently removing undifferentiated PSCs is crucial for the clinical safety of cell-based therapies.

Purpose of the Study:

• To identify and characterize novel small molecules for selective eradication of undifferentiated PSCs.
• To assess the efficacy and safety of these molecules in enriching differentiated cell populations and preventing teratoma formation.

Main Methods:

• Synthesis and screening of novel small molecules for PSC cytotoxicity.
• Co-culture experiments with PSCs and differentiated human neuronal/cardiomyocyte cells.
• Microarray analysis and RNA knockdown studies to elucidate the mechanism of action.
• In vivo teratoma formation assays in SCID mice and zebrafish embryo toxicity tests.

Main Results:

• A series of small molecules demonstrated potent and specific cytotoxicity against undifferentiated PSCs.
• Enrichment of specialized cells by up to 6-fold was achieved without compromising cell viability or function.
• The molecules induce cell death via the PERK/ATF4/DDIT3 ER stress pathway, with a concurrent decrease in ROS levels.
• Pre-transplantation treatment prevented teratoma formation in mice and showed no toxicity in zebrafish embryos.

Conclusions:

• Novel small molecules offer a promising strategy for eliminating contaminating undifferentiated PSCs in cell therapy preparations.
• These compounds are non-toxic and non-teratogenic, supporting their potential for safe in vivo application.
• The findings advance the clinical translation of PSC-based regenerative medicine by addressing a key safety concern.